Bajaj Finserv Healthcare Fund - Growth - Regular Plan

Other Plans and Options
  • 0.83 %Nav, as on 22-01-2026

  • Previous Nav

  • Net Change on 22-01-2026

  • PersonalFN Rating

  • Assets (Cr.)

  • Expense Ratio

Fund Overview Growth | Regular Plan

  • Fund House

  • Launch Date

  • Benchmark

  • Minimum Investment (₹)

  • Minimum Addl Investment (₹)

  • Exit Load (%)

  • Minimum SIP Investment (₹)

  • Minimum STP Investment (₹)

  • Minimum SWP Investment (₹)

  • 52 Week Low Nav (₹)

  • 52 Week Low Nav Date

  • 52 Week High Nav (₹)

  • 52 Week High Nav Date

Fund Objective

The objective of the Scheme is to generate long term capital appreciation by predominantly investing in equity and equity related securities of pharma, healthcare and allied companies.

Fund Performance

Scheme Name 1-Month Return (%) 3-Month Return (%) 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Since Inception
BSE Health Care - TRI N/A N/A N/A N/A N/A N/A
NIFTY 50 - TRI N/A N/A N/A N/A N/A N/A

Returns upto 1 year is Absolute, and above 1 year are Compounded Annualised

Peer Fund Comparison

Scheme Name Launch Date Ratings 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Expense Ratio (%) Assets (Cr.)
Nippon India Pharma Fund-Growth Plan-Growth Jun 05, 2004 -1.49 20.10 14.06 1.82 8,264.71
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund - Cumulative Option Jul 13, 2018 -1.13 25.33 16.15 1.86 6,455.55
SBI HEALTHCARE OPPORTUNITIES FUND - REGULAR PLAN -GROWTH Jul 14, 1999 -3.40 22.03 15.19 1.93 3,989.42
DSP Healthcare Fund - Regular Plan - Growth Nov 30, 2018 -7.40 19.82 14.15 1.92 3,114.33
Mirae Asset Healthcare Fund -Regular Growth Jul 02, 2018 -2.19 19.86 14.24 1.93 2,770.84

Fund Holdings as on 31-December-2025

  • Divi's Laboratories Limited

  • Sun Pharmaceutical Industries Limited

  • Apollo Hospitals Enterprise Limited

  • Aurobindo Pharma Limited

  • Cipla Limited

  • Piramal Pharma Limited

  • Neuland Laboratories Limited

  • Emcure Pharmaceuticals Limited

  • Fortis Healthcare Limited

  • Rubicon Research Limited

  • Max Healthcare Institute Limited January 2026 Future

  • Glenmark Pharmaceuticals Limited

  • Clearing Corporation of India Ltd

  • Lupin Limited

  • Biocon Limited

  • IPCA Laboratories Limited

  • Pfizer Limited

  • Vijaya Diagnostic Centre Limited

  • Eternal Limited

  • Zydus Wellness Limited

  • Sanofi Consumer Healthcare India Limited

  • Godrej Consumer Products Limited

  • GlaxoSmithKline Pharmaceuticals Limited

  • Shaily Engineering Plastics Limited

  • Dr. Lal Path Labs Limited

  • Bajaj Finserv Money Market Fund-Direct Plan-Growth

  • Abbott India Limited

  • Medi Assist Healthcare Services Limited

  • MedPlus Health Services Limited

  • Torrent Pharmaceuticals Limited

  • Rainbow Childrens Medicare Limited

  • Jubilant Pharmova Limited

  • Max Healthcare Institute Limited

  • Hindustan Unilever Limited

  • Syngene International Limited

  • Tata Consumer Products Limited

  • Emami Limited

  • Alembic Pharmaceuticals Limited

  • Mankind Pharma Limited

  • AstraZeneca Pharma India Limited

  • Marico Limited

  • Kwality Walls (India) Limited **

  • Net Receivables / (Payables)

View More

  • Pharmaceuticals & Drugs

  • Hospital & Healthcare Services

  • Household & Personal Products

  • Miscellaneous

  • Business Support

  • e-Commerce

  • Consumer Food

  • Plastic Products

  • Retailing

  • Tea/Coffee

  • Edible Oil

  • Unspecified

View More

Fund Manager

  • Cash

  • Derivatives

  • Equity

  • MFU

View More

About Bajaj Finserv Healthcare Fund

Scheme Analysis

Bajaj Finserv Healthcare Fund is a Equity - Sectoral Fund - Pharma & Health Care fund and belongs to Bajaj Finserv Mutual Fund. It was launched on 27-Dec-2024 and currently has an AUM of ₹326.75 crore. Bajaj Finserv Healthcare Fund is benchmarked against BSE Health Care - TRI as primary index and NIFTY 50 - TRI as secondary index.

The NAV of Bajaj Finserv Healthcare Fund ended up ₹0.08(0.83%)yesterday to ₹9.238.

Among its top 3 holdings the fund has exposure to Divi's Laboratories Limited, and

The Bajaj Finserv Healthcare Fund is managed by Nimesh Chandan and Siddharth Chaudhary.

Fund House Contact

S. No. 208/1B, Lohagaon Viman Nagar Pune - 411014

1800-309-3900
service@bajajamc.com
020-67672550